News
- 2019/11/22
- Nippon Kayaku launches PortrazzaⓇ Injection, a human anti EGFR Monoclonal Antibody
- 2019/10/01
- MicroChem Corp (MCC) has changed its name to Kayaku Advanced Materials, Inc.(KAM)
- 2019/08/21
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Dosage & Administration of Breast Cancer with HER2 Overexpression
- 2019/06/18
- Transfer of Marketing Authorization for humanized anti EGFR Monoclonal Antibody PORTRAZZAⓇ, in JAPAN
- 2019/05/30
- Management Changes (Appointments & Transfers)
- 2019/04/22
- NIPPON KAYAKU and Eli Lilly Enter into Licensing Agreement of Necitumumab, a humanized anti EGFR Monoclonal Antibody, in JAPAN